{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '140', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '10.5', 'Appendix 5: Contraceptive Guidance and Pregnancy Testing', '10.5.1', 'Definitions', 'Women of Childbearing Potential (WOCBP)', 'A woman is considered fertile following menarche and until becoming postmenopausal', 'unless permanently sterile (see below).', 'If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot', 'be confirmed before first dose of study intervention, additional evaluation should be', 'considered.', 'Women in the following categories are not considered WOCBP:', 'Premenarchal', 'Premenopausal female with 1 of the following:', '- Documented hysterectomy', '- Documented bilateral salpingectomy', '- Documented bilateral oophorectomy', 'For individuals with permanent infertility due to an alternate medical cause other than the', 'above (eg, Mullerian agenesis, androgen insensitivity), investigator discretion should be', 'applied to determining study entry.', \"Note: Documentation can come from the site personnel's review of the participant's medical\", 'records, medical examination, or medical history interview.', 'Postmenopausal female', '-', 'A postmenopausal state is defined as no menses for 12 months without an', 'alternative medical cause.', 'A high follicle-stimulating hormone (FSH) level in the postmenopausal range', 'may be used to confirm a postmenopausal state in women not using hormonal', 'contraception or HRT. However, in the absence of 12 months of amenorrhea,', 'confirmation with 2 FSH measurements in the postmenopausal range is', 'required.', 'Females on HRT and whose menopausal status is in doubt will be required to', 'use one of the nonhormonal highly effective contraception methods if they', 'wish to continue their HRT during the study. Otherwise, they must', 'discontinue HRT to allow confirmation of postmenopausal status before study', 'enrollment.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '141', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '10.5.2', 'Contraception Requirements', 'Contraceptives allowed during the study includea:', 'Highly Effective Contraceptive Methods That Have Low User Dependency', 'Failure rate of <1% per year when used consistently and correctly.', 'Progestogen-only subdermal contraceptive implantb', 'Intrauterine hormone-releasing system (IUS)', 'Intrauterine device (IUD)', 'Bilateral tubal occlusion', 'Azoospermic partner (Vasectomized or secondary to medical cause)', 'This is a highly effective contraception method provided that the partner is the sole', 'male sexual partner of the WOCBP and the absence of sperm has been confirmed. If', 'not, an additional highly effective method of contraception should be used. A', 'spermatogenesis cycle is approximately 90 days.', \"Note: Documentation of azoospermia can come from the site personnel's review of\", \"the participant's medical records, medical examination, or medical history interview.\", 'Sexual Abstinence', 'Sexual abstinence is considered a highly effective method only if defined as', 'refraining from heterosexual intercourse during the entire period of risk associated', 'with the study intervention. The reliability of sexual abstinence needs to be evaluated', 'in relation to the duration of the study and the preferred and usual lifestyle of the', 'participant.', 'a. Contraceptive use by men or women should be consistent with local regulations', 'regarding the use of contraceptive methods for participants of clinical studies.', 'b. If locally required, in accordance with Clinical Trial Facilitation Group (CTFG)', 'guidelines, acceptable contraceptive implants are limited to those which inhibit', 'ovulation.', 'c.', 'IUS is a progestin-releasing IUD.', 'Note: The following are not acceptable methods of contraception:', '-', 'Periodic abstinence (calendar, symptothermal, postovulation methods),', 'withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea', 'method (LAM).', '-', 'Male condom with cap, diaphragm, or sponge with spermicide.', '- Male and female condom should not be used together (due to risk of failure with', 'friction).', '10.5.3', 'Pregnancy Testing', 'WOCBP should only be included after a negative highly sensitive urine or serum pregnancy', 'test. Refer to Section 8.3.5.2 and Appendix 2 for further details.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}